Iron Path Capital acquires Boulder Scientific in $450 million Fund II’s first investment

By: ICN Bureau

Last updated : November 16, 2026 4:20 pm



The deal signals Iron Path’s confidence in Boulder Scientific’s technical capabilities and growth potential across highly specialised and regulated industries


Iron Path Capital has acquired Boulder Scientific Company from Quad-C Management, marking the first investment from its newly launched $450 million Fund II as the private equity firm moves to expand its footprint in specialty chemicals and advanced materials.
 
The acquisition brings Boulder Scientific, a Colorado-based manufacturer of high-performance organometallic compounds and provider of complex synthetic chemistry capabilities, into Iron Path Capital’s portfolio. Financial terms of the transaction were not disclosed.
 
The deal signals Iron Path’s confidence in Boulder Scientific’s technical capabilities and growth potential across highly specialised and regulated industries.
 
"Boulder Scientific is a differentiated, technically driven business that clearly aligns with our strategy of partnering with technical companies that have unique capabilities," said Rob Reistetter, Managing Partner at Iron Path Capital.
 
He added: “We are excited to partner with the management team in the Company’s next phase of growth and look forward to supporting continued investment in its capabilities and expansion into existing and new end markets.”
 
Founded in 1961 and headquartered in Longmont, Colorado, Boulder Scientific operates two manufacturing facilities in the state. Its specialty chemicals serve a diverse range of industries, including polyolefins, microelectronics, semiconductors, pharmaceuticals, and aerospace and defence, with customers across the United States and international markets.
 
The company manufactures organometallic compounds, catalysts, activators, ligands, air- and moisture-sensitive compounds, pyrophoric materials and other co-catalysts used in a range of advanced industrial applications.
 
Boulder Scientific CEO Rich Preziotti said the partnership would strengthen the company's ability to pursue its growth ambitions and deepen customer relationships.
 
“The Boulder Scientific team is excited to partner with Iron Path Capital as we execute on our commitment to deliver outstanding science and support to existing and new customers in the target markets that we serve. We are highly optimistic that our growth plans in advanced catalysts, electronics, aerospace and defense, and life sciences will be enhanced through collaboration with Iron Path and the resources available to support Boulder’s continued growth.”
 
For Iron Path Capital, the acquisition represents a strategic deployment of capital from its $450 million Fund II, reinforcing its focus on specialised businesses with differentiated technical capabilities and opportunities for expansion.
 
The firm invests in lower middle-market companies operating in specialty chemicals and materials, engineered products and solutions, and technical services, particularly those serving highly regulated end markets.
 
With the acquisition, Iron Path Capital plans to work alongside Boulder Scientific’s management team to support further investment in its technical capabilities, expand its market reach and accelerate growth across existing and emerging sectors.

Iron Path

First Published : November 16, 2026 12:00 am